Breast cancer and protein biomarkers.

Breast cancer is a healthcare concern of women worldwide. Despite procedures being available for diagnosis, prognosis and treatment of breast cancer, researchers are working intensively on the disease in order to improve the life quality of breast cancer patients. At present, there is no single treatment known to bring a definite cure for breast cancer. One of the possible solutions for combating breast cancer is through identification of reliable protein biomarkers that can be effectively used for early detection, prognosis and treatments of the cancer. Therefore, the task of identification of biomarkers for breast cancer has become the focus of many researchers worldwide.

[1]  C. Richard,et al.  The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis , 2006, Clinical Cancer Research.

[2]  Daohai Zhang,et al.  Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells. , 2010, Experimental cell research.

[3]  L. Gam,et al.  The PCA and LDA Analysis on the Differential Expression of Proteins in Breast Cancer , 2011, Disease markers.

[4]  J. Birch.  Genes and cancer , 1999, Archives of disease in childhood.

[5]  P. Drew,et al.  Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID? , 2012, Journal of proteomics.

[6]  N. Peat,et al.  Structure and biology of a carcinoma-associated mucin, MUC1. , 1991, The American review of respiratory disease.

[7]  S. Barnhill,et al.  CA 125: The past and the Future , 1998, The International journal of biological markers.

[8]  R. Nahta,et al.  Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. , 2009, Current pharmacogenomics and personalized medicine.

[9]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[10]  Enrique Parás Chavero.  The past and the future , 1965 .

[11]  B. Kramer,et al.  Trends in biomarker research for cancer detection. , 2001, The Lancet. Oncology.

[12]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Eberlein,et al.  Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T‐cell activation , 1999, International journal of cancer.

[14]  Kit S. Lam,et al.  A Serum Glycomics Approach to Breast Cancer Biomarkers*S , 2007, Molecular & Cellular Proteomics.

[15]  P. Kantoff,et al.  Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[17]  A. Melnick,et al.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models , 2009, Proceedings of the National Academy of Sciences.

[18]  M. Duffy,et al.  Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? , 2001, Clinical chemistry.

[19]  B. Hulka,et al.  Breast cancer: hormones and other risk factors. , 2001, Maturitas.

[20]  H. Körner,et al.  Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis , 2006, The Journal of pathology.

[21]  K. Baggerly,et al.  Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure , 2010, Proteomics.

[22]  Bin Wen,et al.  Comparative Proteome Analysis of Breast Cancer and Adjacent Normal Breast Tissues in Human , 2006, Genom. Proteom. Bioinform..

[23]  Jing Wang,et al.  Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes , 2008, Nature Immunology.

[24]  E. Petricoin,et al.  Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.

[25]  D. Noh,et al.  Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer. , 2012, Journal of proteome research.

[26]  Mukesh Verma,et al.  Proteomics for Cancer Biomarker Discovery , 2002 .

[27]  P. Drew,et al.  Pilot and feasibility study: comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer. , 2012, Journal of proteomics.

[28]  Stephen Russell,et al.  Proteomics of breast carcinoma. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[29]  L. Chow,et al.  Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance , 2010, Expert opinion on investigational drugs.

[30]  R. Bast,et al.  Status of tumor markers in ovarian cancer screening. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[32]  Hai Hu,et al.  Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. , 2004, Cancer genetics and cytogenetics.

[33]  M. Magee,et al.  Increased mortality associated with elevated carcinoembryonic antigen in insurance applicants. , 2007, Journal of insurance medicine.

[34]  C. Fabian.  Surrogates are just surrogates, but helpful just the same , 2007, Breast Cancer Research.

[35]  V. Levenson,et al.  Biomarkers for early detection of breast cancer: what, when, and where? , 2007, Biochimica et biophysica acta.

[36]  R. Caprioli,et al.  Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation , 2010, Clinical Cancer Research.

[37]  G. Clark.  Interpreting and integrating risk factors for patients with primary breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.

[38]  Yang Zhang,et al.  Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and cyclin E in invasive ductal breast carcinomas. , 2011, Histology and histopathology.

[39]  M. Mandal,et al.  Growth Factor Receptors and Apoptosis Regulators: Signaling Pathways, Prognosis, Chemosensitivity and Treatment Outcomes of Breast Cancer , 2009, Breast cancer : basic and clinical research.

[40]  K. Pritzker,et al.  Cancer biomarkers: easier said than done. , 2002, Clinical chemistry.

[41]  L. Gam,et al.  The Differential Expression of Aqueous Soluble Proteins in Breast Normal and Cancerous Tissues in Relation to Ethnicity of the Patients; Chinese, Malay and Indian , 2010, Disease markers.

[42]  John M S Bartlett,et al.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Robertson,et al.  MUC-1 mucin assays for monitoring therapy in metastatic breast cancer , 1998 .

[44]  F. Révillion,et al.  Proteomic analysis reveals that 14-3-3σ is down-regulated in human breast cancer cells , 2001 .